Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk : A Multi-cohort Model Development Study. / Byrne, Jonah F.; Healy, Colm; Föcking, Melanie; Susai, Subash Raj; Mongan, David; Wynne, Kieran; Kodosaki, Eleftheria; Heurich, Meike; de Haan, Lieuwe; Hickie, Ian B.; Smesny, Stefan; Thompson, Andrew; Markulev, Connie; Young, Alison Ruth; Schäfer, Miriam R.; Riecher-Rössler, Anita; Mossaheb, Nilufar; Berger, Gregor; Schlögelhofer, Monika; Nordentoft, Merete; Chen, Eric Y. H.; Verma, Swapna; Nieman, Dorien H.; Woods, Scott W.; Cornblatt, Barbara A.; Stone, William S.; Mathalon, Daniel H.; Bearden, Carrie E.; Cadenhead, Kristin S.; Addington, Jean; Walker, Elaine F.; Cannon, Tyrone D.; Cannon, Mary; McGorry, Pat; Amminger, Paul; Cagney, Gerard; Nelson, Barnaby; Jeffries, Clark; Perkins, Diana; Cotter, David R.

I: Schizophrenia Bulletin, Bind 50, Nr. 3, 2024, s. 579-588.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Byrne, JF, Healy, C, Föcking, M, Susai, SR, Mongan, D, Wynne, K, Kodosaki, E, Heurich, M, de Haan, L, Hickie, IB, Smesny, S, Thompson, A, Markulev, C, Young, AR, Schäfer, MR, Riecher-Rössler, A, Mossaheb, N, Berger, G, Schlögelhofer, M, Nordentoft, M, Chen, EYH, Verma, S, Nieman, DH, Woods, SW, Cornblatt, BA, Stone, WS, Mathalon, DH, Bearden, CE, Cadenhead, KS, Addington, J, Walker, EF, Cannon, TD, Cannon, M, McGorry, P, Amminger, P, Cagney, G, Nelson, B, Jeffries, C, Perkins, D & Cotter, DR 2024, 'Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study', Schizophrenia Bulletin, bind 50, nr. 3, s. 579-588. https://doi.org/10.1093/schbul/sbad184

APA

Byrne, J. F., Healy, C., Föcking, M., Susai, S. R., Mongan, D., Wynne, K., Kodosaki, E., Heurich, M., de Haan, L., Hickie, I. B., Smesny, S., Thompson, A., Markulev, C., Young, A. R., Schäfer, M. R., Riecher-Rössler, A., Mossaheb, N., Berger, G., Schlögelhofer, M., ... Cotter, D. R. (2024). Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study. Schizophrenia Bulletin, 50(3), 579-588. https://doi.org/10.1093/schbul/sbad184

Vancouver

Byrne JF, Healy C, Föcking M, Susai SR, Mongan D, Wynne K o.a. Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study. Schizophrenia Bulletin. 2024;50(3):579-588. https://doi.org/10.1093/schbul/sbad184

Author

Byrne, Jonah F. ; Healy, Colm ; Föcking, Melanie ; Susai, Subash Raj ; Mongan, David ; Wynne, Kieran ; Kodosaki, Eleftheria ; Heurich, Meike ; de Haan, Lieuwe ; Hickie, Ian B. ; Smesny, Stefan ; Thompson, Andrew ; Markulev, Connie ; Young, Alison Ruth ; Schäfer, Miriam R. ; Riecher-Rössler, Anita ; Mossaheb, Nilufar ; Berger, Gregor ; Schlögelhofer, Monika ; Nordentoft, Merete ; Chen, Eric Y. H. ; Verma, Swapna ; Nieman, Dorien H. ; Woods, Scott W. ; Cornblatt, Barbara A. ; Stone, William S. ; Mathalon, Daniel H. ; Bearden, Carrie E. ; Cadenhead, Kristin S. ; Addington, Jean ; Walker, Elaine F. ; Cannon, Tyrone D. ; Cannon, Mary ; McGorry, Pat ; Amminger, Paul ; Cagney, Gerard ; Nelson, Barnaby ; Jeffries, Clark ; Perkins, Diana ; Cotter, David R. / Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk : A Multi-cohort Model Development Study. I: Schizophrenia Bulletin. 2024 ; Bind 50, Nr. 3. s. 579-588.

Bibtex

@article{d907489ebc974674806abf485b777c68,
title = "Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study",
abstract = "Psychosis risk prediction is one of the leading challenges in psychiatry. Previous investigations have suggested that plasma proteomic data may be useful in accurately predicting transition to psychosis in individuals at clinical high risk (CHR). We hypothesized that an a priori-specified proteomic prediction model would have strong predictive accuracy for psychosis risk and aimed to replicate longitudinal associations between plasma proteins and transition to psychosis. This study used plasma samples from participants in 3 CHR cohorts: the North American Prodrome Longitudinal Studies 2 and 3, and the NEURAPRO randomized control trial (total n = 754). Plasma proteomic data were quantified using mass spectrometry. The primary outcome was transition to psychosis over the study follow-up period. Logistic regression models were internally validated, and optimism-corrected performance metrics derived with a bootstrap procedure. In the overall sample of CHR participants (age: 18.5, SD: 3.9; 51.9% male), 20.4% (n = 154) developed psychosis within 4.4 years. The a priori-specified model showed poor risk-prediction accuracy for the development of psychosis (C-statistic: 0.51 [95% CI: 0.50, 0.59], calibration slope: 0.45). At a group level, Complement C8B, C4B, C5, and leucine-rich α-2 glycoprotein 1 (LRG1) were associated with transition to psychosis but did not surpass correction for multiple comparisons. This study did not confirm the findings from a previous proteomic prediction model of transition from CHR to psychosis. Certain complement proteins may be weakly associated with transition at a group level. Previous findings, derived from small samples, should be interpreted with caution.",
author = "Byrne, {Jonah F.} and Colm Healy and Melanie F{\"o}cking and Susai, {Subash Raj} and David Mongan and Kieran Wynne and Eleftheria Kodosaki and Meike Heurich and {de Haan}, Lieuwe and Hickie, {Ian B.} and Stefan Smesny and Andrew Thompson and Connie Markulev and Young, {Alison Ruth} and Sch{\"a}fer, {Miriam R.} and Anita Riecher-R{\"o}ssler and Nilufar Mossaheb and Gregor Berger and Monika Schl{\"o}gelhofer and Merete Nordentoft and Chen, {Eric Y. H.} and Swapna Verma and Nieman, {Dorien H.} and Woods, {Scott W.} and Cornblatt, {Barbara A.} and Stone, {William S.} and Mathalon, {Daniel H.} and Bearden, {Carrie E.} and Cadenhead, {Kristin S.} and Jean Addington and Walker, {Elaine F.} and Cannon, {Tyrone D.} and Mary Cannon and Pat McGorry and Paul Amminger and Gerard Cagney and Barnaby Nelson and Clark Jeffries and Diana Perkins and Cotter, {David R.}",
note = "{\textcopyright} The Author(s) 2024. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.",
year = "2024",
doi = "10.1093/schbul/sbad184",
language = "English",
volume = "50",
pages = "579--588",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "3",

}

RIS

TY - JOUR

T1 - Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk

T2 - A Multi-cohort Model Development Study

AU - Byrne, Jonah F.

AU - Healy, Colm

AU - Föcking, Melanie

AU - Susai, Subash Raj

AU - Mongan, David

AU - Wynne, Kieran

AU - Kodosaki, Eleftheria

AU - Heurich, Meike

AU - de Haan, Lieuwe

AU - Hickie, Ian B.

AU - Smesny, Stefan

AU - Thompson, Andrew

AU - Markulev, Connie

AU - Young, Alison Ruth

AU - Schäfer, Miriam R.

AU - Riecher-Rössler, Anita

AU - Mossaheb, Nilufar

AU - Berger, Gregor

AU - Schlögelhofer, Monika

AU - Nordentoft, Merete

AU - Chen, Eric Y. H.

AU - Verma, Swapna

AU - Nieman, Dorien H.

AU - Woods, Scott W.

AU - Cornblatt, Barbara A.

AU - Stone, William S.

AU - Mathalon, Daniel H.

AU - Bearden, Carrie E.

AU - Cadenhead, Kristin S.

AU - Addington, Jean

AU - Walker, Elaine F.

AU - Cannon, Tyrone D.

AU - Cannon, Mary

AU - McGorry, Pat

AU - Amminger, Paul

AU - Cagney, Gerard

AU - Nelson, Barnaby

AU - Jeffries, Clark

AU - Perkins, Diana

AU - Cotter, David R.

N1 - © The Author(s) 2024. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.

PY - 2024

Y1 - 2024

N2 - Psychosis risk prediction is one of the leading challenges in psychiatry. Previous investigations have suggested that plasma proteomic data may be useful in accurately predicting transition to psychosis in individuals at clinical high risk (CHR). We hypothesized that an a priori-specified proteomic prediction model would have strong predictive accuracy for psychosis risk and aimed to replicate longitudinal associations between plasma proteins and transition to psychosis. This study used plasma samples from participants in 3 CHR cohorts: the North American Prodrome Longitudinal Studies 2 and 3, and the NEURAPRO randomized control trial (total n = 754). Plasma proteomic data were quantified using mass spectrometry. The primary outcome was transition to psychosis over the study follow-up period. Logistic regression models were internally validated, and optimism-corrected performance metrics derived with a bootstrap procedure. In the overall sample of CHR participants (age: 18.5, SD: 3.9; 51.9% male), 20.4% (n = 154) developed psychosis within 4.4 years. The a priori-specified model showed poor risk-prediction accuracy for the development of psychosis (C-statistic: 0.51 [95% CI: 0.50, 0.59], calibration slope: 0.45). At a group level, Complement C8B, C4B, C5, and leucine-rich α-2 glycoprotein 1 (LRG1) were associated with transition to psychosis but did not surpass correction for multiple comparisons. This study did not confirm the findings from a previous proteomic prediction model of transition from CHR to psychosis. Certain complement proteins may be weakly associated with transition at a group level. Previous findings, derived from small samples, should be interpreted with caution.

AB - Psychosis risk prediction is one of the leading challenges in psychiatry. Previous investigations have suggested that plasma proteomic data may be useful in accurately predicting transition to psychosis in individuals at clinical high risk (CHR). We hypothesized that an a priori-specified proteomic prediction model would have strong predictive accuracy for psychosis risk and aimed to replicate longitudinal associations between plasma proteins and transition to psychosis. This study used plasma samples from participants in 3 CHR cohorts: the North American Prodrome Longitudinal Studies 2 and 3, and the NEURAPRO randomized control trial (total n = 754). Plasma proteomic data were quantified using mass spectrometry. The primary outcome was transition to psychosis over the study follow-up period. Logistic regression models were internally validated, and optimism-corrected performance metrics derived with a bootstrap procedure. In the overall sample of CHR participants (age: 18.5, SD: 3.9; 51.9% male), 20.4% (n = 154) developed psychosis within 4.4 years. The a priori-specified model showed poor risk-prediction accuracy for the development of psychosis (C-statistic: 0.51 [95% CI: 0.50, 0.59], calibration slope: 0.45). At a group level, Complement C8B, C4B, C5, and leucine-rich α-2 glycoprotein 1 (LRG1) were associated with transition to psychosis but did not surpass correction for multiple comparisons. This study did not confirm the findings from a previous proteomic prediction model of transition from CHR to psychosis. Certain complement proteins may be weakly associated with transition at a group level. Previous findings, derived from small samples, should be interpreted with caution.

U2 - 10.1093/schbul/sbad184

DO - 10.1093/schbul/sbad184

M3 - Journal article

C2 - 38243809

VL - 50

SP - 579

EP - 588

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 3

ER -

ID: 387373285